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Abstract 
Objective 
We have assessed the utility of a pre-publication validation policy in reducing the 
probability of publishing false positive research findings.  
Study design and setting 
The large database of the Sylvia Lawry Centre for Multiple Sclerosis Research was split 
in two parts: one for hypothesis generation and a validation part for confirmation of 
selected results. We present case studies from 5 finalized projects that have used the 
validation policy and results from a simulation study. 
Results 
In one project, the “relapse and disability” project as described in section II (example 3), 
findings could not be confirmed in the validation part of the database. The simulation 
study showed that the percentage of false positive findings can exceed 20% depending 
on variable selection.  
Conclusion 
We conclude that the validation policy has prevented the publication of at least one 
research finding that could not be validated in an independent data set (and probably 
would have been a “true” false-positive finding) over the past three years, and has led to 
improved data analysis, statistical programming, and selection of hypotheses. The 
advantages outweigh the lost statistical power inherent in the process.  
 
188 words 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.4
33
.1
 : 
Po
st
ed
 1
2 
Ju
l 2
00
7
 3 
I Introduction  
The validity of published research findings is receiving appropriate scrutiny [1-4]. 
Erroneous conclusions are commonplace [1-4]. Analyses performed on datasets prior to 
focus on specific hypotheses or models do hazard the generation of hypotheses filtered 
through unwitting bias. Hypothesis-generating experiments are necessary but multiple 
model selection may not be capable of identifying valid conclusions. Pre-publication 
validation aims to reduce the number of false positive findings. 
 
Multiple sclerosis is a disease of the nervous system with highly variable outcomes. 
Relapses are characteristic and average 0.5/year [5] in the relapsing phase. Half of 
patients need aid for walking or are worse after 15 years [6]. In clinical trials annualized 
relapse rates and disease progression (as measured by the Expanded Disability Status 
Scale or EDSS) have been used as endpoints. Magnetic resonance imaging (MRI) of 
the brain detects inflammatory activity and change in brain volume. MRI-related 
endpoints include new gadolinium-enhancing lesions and total brain lesion volume (T2 
weighted image) but remain unvalidated surrogates for long-term outcome.  
 
Several medications reduce relapse rate and/or MRI lesions but are uncertain 
suppressors of disease progression. The Sylvia Lawry Centre for MS Research (SLC) 
was developed to improve outcome-based trial research in MS.  We describe the 
background of the SLC, its framework for statistical validation and studies demonstrating 
the Centre’s policies.  
 
The validation policy of the Sylvia Lawry Centre for MS Research 
 
The validation policy of the SLCMSR prescribes a random split into two parts for 
hypothesis generation and validation, a variant of independent replication by split 
sample validation. 
 
Training and validation parts contain 40% and 50% of the data respectively. When new 
databases are added, the remaining 10% of data is used for mixing purposes. The 
training part is available to researchers/statisticians for exploration and investigation and 
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important findings are selected for validation. Approved proposals go to the “data-
trustee”, who evaluates the validation dataset, and summarizes the result for the 
publication/validation committee, the analyst and collaborative researchers. Results 
obtained from the training part of the database, annotated by confirmation information 
are published [7]. 
 
Proactive application of this process applied to SLC projects coming to the final 
validation step is described [8-11]. A common goal in chronic diseases is to find 
predictors of an outcome variable of interest among larger sets of potential explanatory 
variables. These variables can be continuous, binary or count variables and lead in turn 
to linear, logistic, or Poisson regression models. After identification of significant 
predictors in the training portion of the database in a multiple regression model, we 
attempted to confirm these in the validation part of the database. By “successful 
validation” we meant that the same predictors remained significant on a 5% level in a 
multiple regression model in the closed part (see, e.g., Altman). 
 
A simulation study assessed the influence of variable selection on the overall 
significance level. In practice, the distribution of key variables and number of patients in 
the specific subgroups are determined within the validation step to ensure 
correspondence of the datasets. 
 
II Methods 
 
a) Case studies and examples 
 
Example 1 
Relevant to the use of T2 lesion volume as a surrogate marker for disability, we 
investigated the relationship between this MRI outcome variable, and a set of 
continuous, ordinal and binary clinical determinants as potential explanatory variables. 
Unexpectedly, a non-linear plateauing relationship between the ordinal predictor 
“Expanded Disability Status Scale” (EDSS), and the MRI outcome for a set of 1312 
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placebo patients with MS from randomized clinical trials was found (Fig. 1, see [8] for 
details on the variables and results of this project).  
 
 
Figure 1. Plateauing relationship between EDSS and T2 lesion volume in the open part 
of the SLC database [8] 
 
We validated this finding in steps, the key step being whether the EDSS predictor led to 
improvement (p<0.05) of model fit when entered in a nonlinear (as compared to linear) 
fashion. We then calculated Spearman’s correlation coefficient over the range of EDSS 
values and considered the validation of the plateauing relationship successful, if the 
overall correlation with EDSS was positive and significant (p<0.05), and if the correlation 
coefficient for EDSS >4 was not significantly different from zero, (95% confidence 
interval included zero). The size of the validation sample corresponding to this project 
contained 848 patients. The distributions with respect to the key variables were similar in 
training and validation sets, indicating comparability and suitability for validation. All 
predictors assessed were validated in the multiple regression fits. The major finding of a 
plateauing relationship between EDSS and transformed T2 lesion burden was 
unequivocally confirmed – T2 lesion volume does not seem to be a good surrogate for 
disability in MS patients.  
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Example 2 
The development of gadolinium enhancing lesions is often used in phase II clinical MS 
trials to evaluate the potential efficacy of new drugs. The presence of these lesions is 
interpreted as an indicator of acute disease activity in MS patients (see [9]). Predictors of 
enhancement status could be useful for the selection of patients for MRI monitored trials.  
 
In a multiple regression model with clinical and demographic predictors (“disease 
course”, “age at disease onset” and “disease duration”, see [9] for details), the MRI 
predictor “T2 lesion burden” significantly improved the prediction of enhancement status 
in the open part of the SLC database. We then defined the validation to be successful if 
the values of several statistics in the closed part of the database, most importantly the 
positive predictive value, are above the lower endpoints of approximate one-sided 95% 
prediction (99% for “excellent” validation) intervals for the anticipated value in the 
validation part of the database. We found that the increase in positive predictive value 
over the a priori chance of enhancement in the closed database when T2 lesion burden 
was included as predictor exceeded the prespecified level defining “excellent” validation.  
 
Example 3 
We investigated within trials whether relapses contribute to the development of 
subsequent sustained increase of impairment and disability in patients with MS as 
measured by the EDSS (see [10] for details). On-study relapse data was collected in so-
called “sacrifice” periods of 80, 120, 160, or 200 days. Confirmed increase in EDSS was 
defined as at least one point rise confirmed by another visit at least 135 days later. In 
two comparison groups with two different cut-point splits: a) 0 versus at least 1 relapse 
during the sacrifice period, and b) 0 or 1 relapse versus at least 2 relapses during the 
sacrifice period, analysis was based on a two-sided log rank test to determine whether 
time to confirmed rise in EDSS is the same for two groups. Results are displayed in 
terms of hazard ratio and 95% confidence interval. There were 256 relapsing remitting 
MS patients in the training database for this analysis. Combining the four different 
sacrifice periods, and the two different cutpoint splits results in eight tests. The test with 
the smallest p-value was the one for 120 days sacrifice period and cut-point split 0 
versus at least 1 relapse during sacrifice period (likelihood ratio test p-value was 0.0012, 
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estimated hazard ratio = 2.26, 95% confidence interval [1.36; 3.75]). Such a result – if 
validated – would support the assumption that reduction of relapses slows down the 
accumulation of disability.  
 
In the 320 patients available in the validation sample comparable to the training sample 
for distribution of the key variables (p-value of the one-sided Wald test was 0.109) 
findings could not be validated. We concluded that “there is no consistent effect of on-
study relapses on the subsequent development of sustained EDSS score increase 
during a typical clinical study observation period”. 
 
b) Simulation studies and validation cost 
In simulation studies to determine the effect of variable selection on the significance 
level of global F-tests in multiple regression analysis (data not shown), observed error 
rates were found to exceed 20% for both forward and backward selection. With only one 
or two variables in the model, forward selection has more flexibility to identify 
“significant” predictors, leading to more false positive findings than backward selection. 
Forward selection and backward selection produce comparable error rates with 3 or 
more variables. With six predictors in the regression model, forward selection maintains 
the significance level of 5%. 
 
To assess the “cost” of splitting the database we used a one-sided, one-sample Gauss-
test situation with 900 observations, (400 would be available in the training database, 
and 500 for confirmation).  
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Figure 2 displays the power for four different validation scenarios plotted against shift in 
percent of standard deviation: the first for the complete dataset on a 5% significance 
level; the second for testing on the validation stage only (N=500 patients) on 5% 
significance level; the third for testing on the training set (N=400 patients) with 10% and 
on the validation set (N=500) with 5%; and the fourth scenario for testing on a 5% 
significance level in the training data (N=400 patients) and in the validation data (N=500 
patients). There is a sacrifice in power using this validation scheme. 
 
 
III Results  
Since the SLCMSR validation policy was put in place, ten larger scientific projects have 
been finalized using the training portion of the database. In five of them, the findings of 
the training data were selected for confirmation in the validation part of the database. In 
four of these, training dataset findings were replicated in the validation dataset. In one, 
the “relapse and disability” project as described in section II (example 3), findings could 
not be confirmed in the closed portion of the database – without the validation policy this 
would have lead to publication of a false-positive finding. The other five projects were 
finalized without result validation. In each case the authors, committee members and 
journal reviewers agreed that the findings obtained in the training set were sufficient for 
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answering the question at hand. In some cases the hypothesis had clearly been 
formulated before touching the training set. In another example only a rough estimate of 
the upper bound of the mortality rate was proposed to decide about the feasibility of a 
trial design [12,13].  
 
IV Discussion 
 
Exploratory data analysis typically starts with data description entailing comparisons, 
and often generating statistical hypotheses. Ideally, however, all hypotheses should be 
formulated prior to descriptive analysis (or even before data collection). In practice data 
description leads to new questions, to investigation of new relationships by formulating 
hypotheses, and then formal testing. Descriptive statistical analyses can substantially 
endanger the validity of formal statistical inference by destroying the probabilistic basis 
of inferential statistics. 
 
Substantial statistical methodology has been dedicated to overcoming this problem 
including replication, cross-validation, limits for family-wise error rates and Bonferroni-
adjustment for multiple testing [14, 15]. These methods could be applied to control the 
overall significance level for a type I error, but it is usually impossible to quantitate prior 
“data dredging” [15-17]. 
 
Significance levels can be controlled by dividing the data set into separate parts prior to 
data analysis. Hastie et al. [16], for example, recommend randomly splitting the 
database into 1) a training set, 2) a validation set, and 3) a test set to evaluate the 
predictive accuracy of the model. Van Houwelingen and le Cessie [18] suggest using 
one part of the database to select the covariates, a second to estimate the regression 
coefficients, and a third to assess the prediction rule. 
 
The SLCMSR hosts a large database on multiple sclerosis patients from clinical trials 
and natural history studies. Data donors do not influence the publication process, and 
SLCMSR follows strict rules guaranteeing non-identifiability of individual data sets. 
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Anonymization and splitting of the trials make it impossible for SLCMSR and 
collaborative researchers to identify patients and trials with individual data donors.  
 
Splitting the large SLC database into two parts yields one training part for hypothesis 
generation, and a second for validation purposes. Only large databases are suitable for 
splitting, because in secondary analyses patient numbers drop considerably. The 
validation part of the database is reserved for confirmation of single pre-specified 
hypotheses. The major finding of one otherwise finalized project could not be validated, 
and the publication of a false-positive finding was prevented. We believe that having this 
validation policy leads to a more sensible and thorough data analysis, programming and 
code checking, and selection of hypotheses to validate. 
 
Simulations of the true significance level under the null hypothesis of global F-tests after 
forward and backward variable selection showed (N=746) that the significance level can 
easily go beyond 20% when only a small number of predictor variables are included in 
the model.  
 
The price to pay for splitting the database is a reduction in statistical power. We 
simulated power levels similar to a typical study at the SLC, and we demonstrated that 
the shift in percent of standard deviation for a one-sided Gauss-test detected with 80% 
power needs to be nearly double the size with result validation than without result 
validation. In other words, statistically significant findings need to be detected twice: in 
the training sample and in the validation sample. However, the price of publishing false 
positive research findings in a field with many false dawns justifies validation efforts. 
 
Is the proposed method of result validation generally suitable for research questions or 
databases? We think that properly designed randomized controlled clinical trials do not 
need result validation. Even when additional hypotheses are to be tested at the end of 
the trial, Bonferroni adjustments can be sufficient to control the significance level. 
Epidemiological studies, however, are not scientific experiments, and, the study design 
is less structured than in clinical trials, and often lacking randomization. In addition false-
positive findings from large-scale studies cannot be disproved since other studies are 
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typically smaller and do not have the power to do so. When a large group of researchers 
works on a scientific field using the same database, result validation is a powerful way to 
reduce the probability of publishing false positive findings.  
 
Ioannidis [1] states that there is no “gold-standard” for validation in general, but that the 
percentage of published false positive findings can be reduced by better-powered 
studies, i.e. large-scale studies, low-bias meta-analyses, registration of studies and 
networking of data collections – similar to randomized controlled trials, and a split-team 
approach. 
 
Words 2342 
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